QuidelOrtho Corp

QuidelOrtho Corporation develops diagnostic testing solutions, laboratory instruments, and related services. Its business units comprise Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics, organized geographically into North America, EMEA, China, JPAC, and Latin America. Offerings include clinical chemistry systems, immunoassays, blood typing instruments, donor screening assays, molecular testing platforms, and rapid point-of-care tests, supplemented by informatics software. Customers include hospitals, clinical laboratories, reference labs, physician offices, urgent care and retail clinics, pharmacies, blood banks, donor centers, and over-the-counter consumers.

The company reaches customers in more than 140 countries and territories, supported by over 2,500 commercial personnel and approximately 1,200 service employees. It maintains production facilities in the United States, the United Kingdom, and China, with main distribution hubs in North America and Europe. QuidelOrtho also operates shared service centers in Ireland, the Czech Republic, France, China, India, and Singapore. The text does not disclose the company's headquarters.

Summary of the business section of QuidelOrtho's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 28, 2025, we had approximately 6,500 employees worldwide, with approximately 3,600 employees in the U.S.”